Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) Sees Significant Growth in Short Interest

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) was the recipient of a large growth in short interest in February. As of February 15th, there was short interest totalling 11,000 shares, a growth of 32.5% from the January 31st total of 8,300 shares. Based on an average daily trading volume, of 17,500 shares, the days-to-cover ratio is currently 0.6 days.

Santen Pharmaceutical Price Performance

Shares of OTCMKTS SNPHY traded down $0.01 during mid-day trading on Tuesday, hitting $9.25. The company had a trading volume of 8,565 shares, compared to its average volume of 12,859. The firm has a 50-day simple moving average of $9.78 and a two-hundred day simple moving average of $11.02. Santen Pharmaceutical has a one year low of $8.65 and a one year high of $13.00.

Santen Pharmaceutical Company Profile

Santen Pharmaceutical Co, Ltd. engages in the research and development, manufacture, and marketing of pharmaceuticals and medical devices in Japan and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2a derivative and a beta-adrenergic receptor blocker; and netarsudil mesilate and latanoprost, a prostaglandin F2a derivative which is marketing approval phase for the treatment of glaucoma and ocular hypertension.